https://www.biopharmawatch.com/news/LLY/lilly-licenses-speechdx-dataset-alzheimers-research BiopharmaWatch en 2026-10-28T15:43:00.000Z Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Licenses SpeechDx Dataset to Eli Lilly and Company, Advancing Speech-Based Markers as a Critical Alzheimer's Research Tool https://www.biopharmawatch.com/news/GMAB/genmab-petosemtamab-head-neck-cancer-trial-results BiopharmaWatch en 2026-10-28T13:40:00.000Z Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer https://www.biopharmawatch.com/news/COSM/noble-capital-markets-initiates-coverage-cosmos-health BiopharmaWatch en 2026-10-28T13:20:00.000Z Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target https://www.biopharmawatch.com/news/OSRH/osr-health-shareholder-update-nasdaq-decision BiopharmaWatch en 2026-10-28T13:15:00.000Z OSR Health Provides Shareholder Update Following Nasdaq Panel Decision https://www.biopharmawatch.com/news/LGVN/longeveron-engages-lucid-capital-markets BiopharmaWatch en 2026-10-28T13:15:00.000Z Longeveron Announces Engagement of Lucid Capital Markets https://www.biopharmawatch.com/news/LEXX/lexaria-celebrates-70th-patent-award BiopharmaWatch en 2026-10-28T13:12:55.000Z Lexaria Celebrates its 70th Patent Award https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-rob-scott-board-directors BiopharmaWatch en 2026-10-28T13:00:24.000Z Arcutis Appoints Rob Scott, MD to Board of Directors https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-rob-scott-to-board BiopharmaWatch en 2026-10-28T13:00:24.000Z Arcutis Appoints Rob Scott, MD to Board of Directors https://www.biopharmawatch.com/news/ILMN/illuminate-rx-expands-affordability-sempre-health-partnership BiopharmaWatch en 2026-10-28T13:00:00.000Z Illuminate Rx Expands Member Affordability Through Sempre Health Partnership https://www.biopharmawatch.com/news/OPK/opko-health-q3-2026-results-report BiopharmaWatch en 2026-10-28T12:52:00.000Z OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/DARE/dare-bioscience-womens-health-focus-investor-discussion BiopharmaWatch en 2026-10-28T12:47:00.000Z Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-phase-3-regal-trial-update BiopharmaWatch en 2026-10-28T12:35:00.000Z SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia https://www.biopharmawatch.com/news/PALI/palisade-bio-first-patient-dosed-ascentra-uc-study BiopharmaWatch en 2026-10-28T12:32:00.000Z Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis https://www.biopharmawatch.com/news/BEAT/heartbeam-align-acs-study-results-tct-2026 BiopharmaWatch en 2026-10-28T12:31:00.000Z HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026 https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-trial-data-presentation-precision-liver-symposium BiopharmaWatch en 2026-10-28T12:31:00.000Z MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 https://www.biopharmawatch.com/news/SUPN/chloe-kim-ms-represented-campaign-adhd BiopharmaWatch en 2026-10-28T12:30:00.000Z Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign https://www.biopharmawatch.com/news/VIR/vir-biotechnology-suzanne-topalian-appointment BiopharmaWatch en 2026-10-28T12:30:00.000Z Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors https://www.biopharmawatch.com/news/SDGR/schrodinger-presents-ubs-global-healthcare-conference BiopharmaWatch en 2026-10-28T12:30:00.000Z Schrödinger to Present at UBS Global Healthcare Conference https://www.biopharmawatch.com/news/EOLS/evolus-investor-conferences-new-york-london BiopharmaWatch en 2026-10-28T12:30:00.000Z Evolus to Participate in Upcoming Investor Conferences in New York and London https://www.biopharmawatch.com/news/EVGN/evogene-aGVHD-ai-drug-discovery-program BiopharmaWatch en 2026-10-28T12:30:00.000Z Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2026-q3-financial-results BiopharmaWatch en 2026-10-28T12:30:00.000Z Spectral AI Schedules 2026 Third Quarter Financial Results and Conference Call https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-partnership-usm-alpha-gal-syndrome BiopharmaWatch en 2026-10-28T12:30:00.000Z 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-phase-1b-study-advanced-cancer BiopharmaWatch en 2026-10-28T12:30:00.000Z Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-appoints-neera-clase-cco BiopharmaWatch en 2026-10-28T12:30:00.000Z Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer https://www.biopharmawatch.com/news/RNXT/renovorx-participate-canaccord-genuity-forum BiopharmaWatch en 2026-10-28T12:30:00.000Z RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/MXCT/maxcyte-participate-investor-conferences-2026 BiopharmaWatch en 2026-10-28T12:05:00.000Z MaxCyte to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/URGN/urogen-olympus-five-year-study-results-jelmyto BiopharmaWatch en 2026-10-28T12:00:00.000Z UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer https://www.biopharmawatch.com/news/WAT/waters-ai-powered-peak-integration-empower-software BiopharmaWatch en 2026-10-28T12:00:00.000Z Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software https://www.biopharmawatch.com/news/DXCM/dexcom-g7-launch-canada-november BiopharmaWatch en 2026-10-28T12:00:00.000Z Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-express-screening-antibodies BiopharmaWatch en 2026-10-28T12:00:00.000Z Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies https://www.biopharmawatch.com/news/AZN/astrazeneca-mark-paul-gosselaar-meet-your-mark-campaign BiopharmaWatch en 2026-10-28T12:00:00.000Z AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing https://www.biopharmawatch.com/news/COYA/coya-therapeutics-nfl-biomarker-stratification-neals-2026 BiopharmaWatch en 2026-10-28T12:00:00.000Z Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting https://www.biopharmawatch.com/news/PYPD/polypid-expands-pipeline-introduces-pd01b BiopharmaWatch en 2026-10-28T12:00:00.000Z PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections https://www.biopharmawatch.com/news/ENLV/enlivex-announces-randomization-135-patients-phase-2b-trial-allocetra-age BiopharmaWatch en 2026-10-28T12:00:00.000Z Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis https://www.biopharmawatch.com/news/IMMP/immutep-receives-a2-16-million-french-tax-incentive BiopharmaWatch en 2026-10-28T12:00:00.000Z Immutep Receives A$2.16 million French R&D Tax Incentive https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-simufilam-preclinical-findings BiopharmaWatch en 2026-10-28T12:00:00.000Z Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells https://www.biopharmawatch.com/news/ECOR/electrocore-quell-fda-clearance-cipn BiopharmaWatch en 2026-10-28T12:00:00.000Z electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) https://www.biopharmawatch.com/news/ANNX/annexon-virtual-investor-event-archer-ii-trial BiopharmaWatch en 2026-10-28T12:00:00.000Z Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-4-5-million-offering BiopharmaWatch en 2026-10-28T12:00:00.000Z INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement https://www.biopharmawatch.com/news/GERN/geron-phase-3-impactmf-trial-update BiopharmaWatch en 2026-10-28T12:00:00.000Z Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis https://www.biopharmawatch.com/news/HUMA/humacyte-us-patent-symvess-bioengineered-tissues BiopharmaWatch en 2026-10-28T12:00:00.000Z Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues https://www.biopharmawatch.com/news/PRQR/proqr-present-clinical-preclinical-progress-ax-0810-ax-0811 BiopharmaWatch en 2026-10-28T12:00:00.000Z ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences https://www.biopharmawatch.com/news/BWAY/brainsway-q3-2026-financial-results-report BiopharmaWatch en 2026-10-28T12:00:00.000Z BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-positive-results-bb-301 BiopharmaWatch en 2026-10-28T12:00:00.000Z Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-safety-results-therapeutic-study BiopharmaWatch en 2026-10-28T11:45:00.000Z Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation https://www.biopharmawatch.com/news/SIGA/siga-contract-15-million-canadian-defence BiopharmaWatch en 2026-10-28T11:30:00.000Z SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX® https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-investor-conferences-2026 BiopharmaWatch en 2026-10-28T11:30:00.000Z Pyxis Oncology to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PVLA/palvella-fda-acceptance-priority-review-qtorin-rapamycin BiopharmaWatch en 2026-10-28T11:30:00.000Z Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set https://www.biopharmawatch.com/news/MLYS/mineralys-phase-2-explore-ckd-trial-results BiopharmaWatch en 2026-10-28T11:05:00.000Z Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International https://www.biopharmawatch.com/news/QURE/uniqure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-28T11:05:00.000Z uniQure to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AXGN/axogen-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T11:02:00.000Z Axogen, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fda-clearance-treprostinil-iloprost BiopharmaWatch en 2026-10-28T11:00:00.000Z United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-28T11:00:00.000Z Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-ceo-retirement-announcement BiopharmaWatch en 2026-10-28T11:00:00.000Z Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership https://www.biopharmawatch.com/news/NVCR/novocure-evaluate-ttfields-therapy-vs7375-pancreatic-cancer BiopharmaWatch en 2026-10-28T11:00:00.000Z Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement https://www.biopharmawatch.com/news/CSTL/castle-biosciences-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-28T11:00:00.000Z Castle Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/GNPX/genprex-tusc2-research-gsa-2026-meharry BiopharmaWatch en 2026-10-28T11:00:00.000Z Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/HCSG/creek-equity-healthcare-services-portfolio BiopharmaWatch en 2026-10-28T11:00:00.000Z Scott Zack's Creek Equity Details Healthcare Services Portfolio Spanning Supply Chain, Pharmacy Benefits, and Medical Courier Logistics https://www.biopharmawatch.com/news/ADAG/adagene-first-patient-phase-1-muzastotug BiopharmaWatch en 2026-10-28T11:00:00.000Z Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-host-person-kol-event-discuss-roluperidone-negative-symptoms BiopharmaWatch en 2026-10-28T11:00:00.000Z Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia https://www.biopharmawatch.com/news/AMRN/amarin-reports-positive-net-income-q3-2026 BiopharmaWatch en 2026-10-28T11:00:00.000Z Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-2027-financial-results-provides-corporate BiopharmaWatch en 2026-10-28T11:00:00.000Z Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q3-2026-earnings-call BiopharmaWatch en 2026-10-28T11:00:00.000Z Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-appoints-chuck-silberstein-cfo BiopharmaWatch en 2026-10-28T11:00:00.000Z NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer https://www.biopharmawatch.com/news/GLUE/monte-rosa-phase-2-study-mrt-6160-psoriatic-arthritis BiopharmaWatch en 2026-10-28T11:00:00.000Z Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) https://www.biopharmawatch.com/news/ADMA/adma-biologics-q3-2026-financial-results BiopharmaWatch en 2026-10-28T11:00:00.000Z ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-november-2026 BiopharmaWatch en 2026-10-28T11:00:00.000Z Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 https://www.biopharmawatch.com/news/BLCO/bausch-lomb-third-quarter-performance-2026 BiopharmaWatch en 2026-10-28T10:58:00.000Z Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance https://www.biopharmawatch.com/news/LH/labcorp-reports-strong-2026-q3-results BiopharmaWatch en 2026-10-28T10:54:22.476Z Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance https://www.biopharmawatch.com/news/BDX/bd-liverty-tips-stent-graft-launch BiopharmaWatch en 2026-10-28T10:50:00.000Z BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-a1c-reduction-weight-loss-ozempic BiopharmaWatch en 2026-10-28T10:45:00.000Z Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial https://www.biopharmawatch.com/news/CMPS/compass-pathways-neuroscience-education-congress-2026 BiopharmaWatch en 2026-10-28T10:30:00.000Z Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress https://www.biopharmawatch.com/news/BSX/boston-scientific-q3-2026-results BiopharmaWatch en 2026-10-28T10:30:00.000Z Boston Scientific announces results for third quarter 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-10-28T10:20:00.000Z GE HealthCare reports third quarter 2026 financial results https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T10:09:10.092Z Avantor® Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/BIIB/biogen-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T10:00:00.000Z Biogen Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/RAPP/rapport-pricing-underwritten-offerings-common-stock-notes BiopharmaWatch en 2026-10-28T10:00:00.000Z Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement https://www.biopharmawatch.com/news/TMO/thermo-fisher-junior-innovators-challenge-2026 BiopharmaWatch en 2026-10-28T02:37:00.000Z 15-year-old Designs Low-Cost Device to Monitor Airborne Bacteria in the Environment; Wins $25,000 Top Award at the 2026 Thermo Fisher Scientific Junior Innovators Challenge https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-fourth-quarter-dividend BiopharmaWatch en 2026-10-27T22:27:00.000Z AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND https://www.biopharmawatch.com/news/ZURA/zura-bio-inducement-grants-nasdaq BiopharmaWatch en 2026-10-27T22:00:00.000Z Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q3-financial-results-2026 BiopharmaWatch en 2026-10-27T22:00:00.000Z Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets https://www.biopharmawatch.com/news/IVF/invo-fertility-reverse-stock-split-october-2026 BiopharmaWatch en 2026-10-27T22:00:00.000Z INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026 https://www.biopharmawatch.com/news/URGN/urogen-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-27T22:00:00.000Z UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:43:00.000Z ICON Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/NVST/envista-2025-sustainability-report BiopharmaWatch en 2026-10-27T20:34:00.000Z Envista Announces Release of 2025 Sustainability Report https://www.biopharmawatch.com/news/RAPP/rapport-announces-public-offerings-concurrent-private-placement BiopharmaWatch en 2026-10-27T20:32:00.000Z Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement https://www.biopharmawatch.com/news/DBVT/dbv-technologies-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:30:00.000Z DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 https://www.biopharmawatch.com/news/CARL/carlsmed-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-27T20:30:00.000Z Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/PACS/pacs-group-third-quarter-2026-earnings-release BiopharmaWatch en 2026-10-27T20:22:00.000Z PACS Group Schedules Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/UHS/universal-health-services-financial-results-september-2026 BiopharmaWatch en 2026-10-27T20:16:27.000Z Universal Health Services, Inc. Announces Financial Results for the Three and Nine-Month Periods Ended September 30, 2026 https://www.biopharmawatch.com/news/ILMN/illumina-webcast-investor-conference-november-2026 BiopharmaWatch en 2026-10-27T20:15:00.000Z Illumina To Webcast Upcoming Investor Conference https://www.biopharmawatch.com/news/PETS/petmed-express-q2-fiscal-year-2027-results BiopharmaWatch en 2026-10-27T20:15:00.000Z PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026 https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:15:00.000Z Chemed Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/ENSG/ensign-group-q3-2026-results-guidance BiopharmaWatch en 2026-10-27T20:08:00.000Z The Ensign Group Reports Third Quarter 2026 Results; Raises 2026 Annual Earnings Guidance https://www.biopharmawatch.com/news/ELMD/electromed-q1-fiscal-2027-results-report BiopharmaWatch en 2026-10-27T20:07:00.000Z Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-third-quarter-results-update BiopharmaWatch en 2026-10-27T20:05:00.000Z Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call https://www.biopharmawatch.com/news/BNGO/bionano-report-q3-2026-results-webcast BiopharmaWatch en 2026-10-27T20:05:00.000Z Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026 https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q3-2026 BiopharmaWatch en 2026-10-27T20:05:00.000Z Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-appoints-leila-alland-cmo BiopharmaWatch en 2026-10-27T20:05:00.000Z Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer https://www.biopharmawatch.com/news/ANL/adlai-nortye-an4035-update-eortc-nci-aacr-symposium BiopharmaWatch en 2026-10-27T20:05:00.000Z Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/KIDS/orthopediatrics-fda-clearance-pnp-retrograde-nail-system BiopharmaWatch en 2026-10-27T20:05:00.000Z OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations https://www.biopharmawatch.com/news/TELA/tela-bio-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-27T20:05:00.000Z TELA Bio to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SI/shoulder-innovations-investor-conferences BiopharmaWatch en 2026-10-27T20:05:00.000Z Shoulder Innovations to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TXG/10x-genomics-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-10-27T20:05:00.000Z 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2026-financial-results-increases-2026 BiopharmaWatch en 2026-10-27T20:05:00.000Z OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance https://www.biopharmawatch.com/news/PACB/pacbio-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-27T20:05:00.000Z PacBio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/RVMD/revolution-medicines-investor-conferences-november-2026 BiopharmaWatch en 2026-10-27T20:05:00.000Z Revolution Medicines to Participate in November 2026 Investor Conferences https://www.biopharmawatch.com/news/OM/outset-medical-2026-stifel-healthcare-conference BiopharmaWatch en 2026-10-27T20:05:00.000Z Outset Medical to Participate in the 2026 Stifel Healthcare Conference https://www.biopharmawatch.com/news/LLY/patrik-jonsson-retirement-ilya-yuffa-president-lilly-global-markets BiopharmaWatch en 2026-10-27T20:03:00.000Z Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets https://www.biopharmawatch.com/news/BBNX/beta-bionics-q3-2026-financial-results BiopharmaWatch en 2026-10-27T20:02:00.000Z Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance https://www.biopharmawatch.com/news/GRAL/grail-presents-ubs-global-healthcare-conference BiopharmaWatch en 2026-10-27T20:02:00.000Z GRAIL to Present at the UBS Global Healthcare Conference https://www.biopharmawatch.com/news/LGND/ligand-participate-november-investor-conferences-20261027 BiopharmaWatch en 2026-10-27T20:01:00.000Z Ligand to Participate in November Investor Conferences https://www.biopharmawatch.com/news/STAA/staar-surgical-investor-conferences-november-2026 BiopharmaWatch en 2026-10-27T20:01:00.000Z STAAR Surgical to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-third-quarter-2026-results BiopharmaWatch en 2026-10-27T20:01:00.000Z Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026 https://www.biopharmawatch.com/news/COGT/cogent-biosciences-guggenheim-conference-participation BiopharmaWatch en 2026-10-27T20:01:00.000Z Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q3-2026-results-investor-day BiopharmaWatch en 2026-10-27T20:01:00.000Z Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation https://www.biopharmawatch.com/news/ARVN/arvinas-early-career-researcher-award-2026 BiopharmaWatch en 2026-10-27T20:01:00.000Z Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation https://www.biopharmawatch.com/news/NRC/nrc-health-q3-2026-results BiopharmaWatch en 2026-10-27T20:00:00.000Z NRC Health Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/AMGN/amgen-new-data-acr-convergence-2026 BiopharmaWatch en 2026-10-27T20:00:00.000Z AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 https://www.biopharmawatch.com/news/ARQT/arcutis-presentation-guggenheim-healthcare-conference BiopharmaWatch en 2026-10-27T20:00:00.000Z Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/AZN/breast-cancer-canada-astrazeneca-survivorship-research BiopharmaWatch en 2026-10-27T18:40:00.000Z Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research https://www.biopharmawatch.com/news/MODD/modular-medical-positive-iso-certification BiopharmaWatch en 2026-10-27T15:50:00.000Z Modular Medical Announces Positive Notified Body Decision on ISO 13485:2016 Certification https://www.biopharmawatch.com/news/ARWR/redeemplo-new-treatment-fcs-england-wales BiopharmaWatch en 2026-10-27T15:36:00.000Z Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides https://www.biopharmawatch.com/news/UNH/codoxo-unitedhealth-fraud-strategies-nhcaa-2026 BiopharmaWatch en 2026-10-27T14:00:00.000Z Beyond Claims Data: Codoxo and UnitedHealth Group to Present Innovative Strategies for Uncovering Healthcare Fraud at NHCAA 2026 https://www.biopharmawatch.com/news/NNVC/nv-387-ebola-treatment-phase-ii-trial-update BiopharmaWatch en 2026-10-27T13:33:36.643Z As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides https://www.biopharmawatch.com/news/CHRS/coherus-participate-upcoming-investor-conferences-20261027 BiopharmaWatch en 2026-10-27T13:30:00.000Z Coherus to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-anal-cancer-data BiopharmaWatch en 2026-10-27T13:30:00.000Z Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers https://www.biopharmawatch.com/news/NXL/nexalin-15ma-difs-improves-sleep-quality-alzheimers BiopharmaWatch en 2026-10-27T13:00:00.000Z Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease https://www.biopharmawatch.com/news/PLUR/pluri-investor-conference-calls-updates BiopharmaWatch en 2026-10-27T13:00:00.000Z Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments https://www.biopharmawatch.com/news/XGN/exagen-announces-q3-financial-results-november-10-2026 BiopharmaWatch en 2026-10-27T13:00:00.000Z Exagen to Announce Third Quarter Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ATYR/atyr-pharma-reverse-stock-split BiopharmaWatch en 2026-10-27T13:00:00.000Z aTyr Pharma Announces One-for-40 Reverse Stock Split https://www.biopharmawatch.com/news/VNRX/volitionrx-missionpharma-lateral-flow-technology-netosis BiopharmaWatch en 2026-10-27T12:47:00.000Z VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-micvo-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-10-27T12:45:00.000Z Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://www.biopharmawatch.com/news/ICCM/icecure-first-cryoablation-treatment-choicestudy BiopharmaWatch en 2026-10-27T12:33:00.000Z IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation https://www.biopharmawatch.com/news/COCH/envoy-medical-q3-2026-financial-results BiopharmaWatch en 2026-10-27T12:30:00.000Z Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5th https://www.biopharmawatch.com/news/DCTH/delcath-systems-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-27T12:30:00.000Z Delcath Systems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AMGN/nord-amgen-learning-collaborative-rare-disease BiopharmaWatch en 2026-10-27T12:30:00.000Z NORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care https://www.biopharmawatch.com/news/MBOT/microbot-medical-first-obl-customer-liberty-system BiopharmaWatch en 2026-10-27T12:30:00.000Z Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System https://www.biopharmawatch.com/news/ONCO/onconetix-acquisition-realbotix-echo-robot-launch BiopharmaWatch en 2026-10-27T12:30:00.000Z Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement https://www.biopharmawatch.com/news/NXGL/nexgel-regains-compliance-nasdaq-listing-requirement BiopharmaWatch en 2026-10-27T12:30:00.000Z NEXGEL Regains Compliance with Nasdaq Listing Requirement https://www.biopharmawatch.com/news/CMND/clearmind-completes-patient-recruitment-aud-trial BiopharmaWatch en 2026-10-27T12:22:00.000Z Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-partial-prepayment-convertible-note BiopharmaWatch en 2026-10-27T12:17:00.000Z VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash https://www.biopharmawatch.com/news/PLRZ/polyrizon-completes-enrollment-nasarix-allergy-blocker BiopharmaWatch en 2026-10-27T12:16:00.000Z Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-study-results BiopharmaWatch en 2026-10-27T12:06:00.000Z 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients https://www.biopharmawatch.com/news/BFLY/butterfly-network-presents-ubs-healthcare-conference-2026 BiopharmaWatch en 2026-10-27T12:05:00.000Z Butterfly Network to Present at UBS Global Healthcare Conference on November 10, 2026 https://www.biopharmawatch.com/news/HLF/herbalife-renews-commitment-red-cross-blood-saves-lives BiopharmaWatch en 2026-10-27T12:05:00.000Z Herbalife renews $1 million in-kind commitment to American Red Cross Blood Saves Lives program https://www.biopharmawatch.com/news/BLLN/billiontoone-participate-investor-conferences BiopharmaWatch en 2026-10-27T12:05:00.000Z BillionToOne to Participate in Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-november-investor-conferences BiopharmaWatch en 2026-10-27T12:05:00.000Z Candel Therapeutics to Present at November Investor Conferences https://www.biopharmawatch.com/news/BFRG/vin-singh-keynote-aiddd-summit BiopharmaWatch en 2026-10-27T12:02:00.000Z BullFrog AI Founder and CEO Vin Singh to Deliver Keynote at AIDDD Summit https://www.biopharmawatch.com/news/VYGR/voyager-gene-therapy-vy1706-anti-tau-antibody-vy7523-ctad-2026 BiopharmaWatch en 2026-10-27T12:01:00.000Z Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-co-founders-transition-leadership BiopharmaWatch en 2026-10-27T12:00:30.000Z Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development https://www.biopharmawatch.com/news/MGTX/meiragtx-posters-esgct-neals-2026 BiopharmaWatch en 2026-10-27T12:00:29.000Z MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting https://www.biopharmawatch.com/news/ABSI/absci-participate-investor-conferences BiopharmaWatch en 2026-10-27T12:00:29.000Z Absci to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ABSI/absci-participate-upcoming-investor-conferences-20261027 BiopharmaWatch en 2026-10-27T12:00:29.000Z Absci to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CDT/cdt-partners-manoira-animal-health-products-launch BiopharmaWatch en 2026-10-27T12:00:00.000Z CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch https://www.biopharmawatch.com/news/TEVA/teva-acquires-bxcl501-worldwide-rights BiopharmaWatch en 2026-10-27T12:00:00.000Z Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline https://www.biopharmawatch.com/news/CRL/charles-river-virtual-control-groups-glp-studies BiopharmaWatch en 2026-10-27T12:00:00.000Z Charles River Leverages Virtual Control Groups in GLP Studies https://www.biopharmawatch.com/news/ABBV/abbvie-bla-etentamig-multiple-myeloma BiopharmaWatch en 2026-10-27T12:00:00.000Z AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma https://www.biopharmawatch.com/news/OGN/entera-appoints-dr-arjona-ferreira-board BiopharmaWatch en 2026-10-27T12:00:00.000Z Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-phase-2a-cadisegliatin-study BiopharmaWatch en 2026-10-27T12:00:00.000Z vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems https://www.biopharmawatch.com/news/SYK/stryker-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-10-27T12:00:00.000Z Stryker to participate in the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/ENLV/enlivex-delisting-notice-nasdaq-appeal BiopharmaWatch en 2026-10-27T12:00:00.000Z Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal https://www.biopharmawatch.com/news/ALT/altimmune-appoints-greenleaf-howarth-board-directors BiopharmaWatch en 2026-10-27T12:00:00.000Z Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q3-2026 BiopharmaWatch en 2026-10-27T12:00:00.000Z Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results https://www.biopharmawatch.com/news/MDGL/madrigal-presents-abstracts-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-27T12:00:00.000Z Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-esmo-2026-cld-401-data BiopharmaWatch en 2026-10-27T12:00:00.000Z Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-pricing-public-offering BiopharmaWatch en 2026-10-27T12:00:00.000Z Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-cta-approval-phase-1-2-trial-cmp-002 BiopharmaWatch en 2026-10-27T12:00:00.000Z CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union https://www.biopharmawatch.com/news/OPK/opko-biologics-phase-1-2a-trial-opk-8801001 BiopharmaWatch en 2026-10-27T12:00:00.000Z OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-10-27T12:00:00.000Z Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 https://www.biopharmawatch.com/news/NTRA/natera-esmo-congress-2026-bladder-cancer BiopharmaWatch en 2026-10-27T11:45:00.000Z Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer https://www.biopharmawatch.com/news/CODX/cosara-diagnostics-tuberculosis-test-launch-india BiopharmaWatch en 2026-10-27T11:45:00.000Z Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-bci-growth-strategy BiopharmaWatch en 2026-10-27T11:45:00.000Z Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform https://www.biopharmawatch.com/news/ZURA/zura-bio-third-quarter-2026-results BiopharmaWatch en 2026-10-27T11:30:00.000Z Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/NGNE/neurogene-ngn-401-data-esgct-congress BiopharmaWatch en 2026-10-27T11:30:00.000Z Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome https://www.biopharmawatch.com/news/JNJ/johnson-johnson-enterprise-business-review-2026 BiopharmaWatch en 2026-10-27T11:30:00.000Z Johnson & Johnson to Host Enterprise Business Review https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-27T11:30:00.000Z Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution https://www.biopharmawatch.com/news/IFRX/inflarx-announces-november-investor-events BiopharmaWatch en 2026-10-27T11:30:00.000Z InflaRx Announces November Investor Events https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-discontinues-allonk-development BiopharmaWatch en 2026-10-27T11:30:00.000Z Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK® https://www.biopharmawatch.com/news/MDCX/medicus-pharma-presents-biofuture-global-biotech-summit BiopharmaWatch en 2026-10-27T11:30:00.000Z Medicus Pharma to Present at BioFuture and Global Biotechnology Summit https://www.biopharmawatch.com/news/CNSY/cerenome-interim-update-respect-lm-trial BiopharmaWatch en 2026-10-27T11:30:00.000Z Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q3-2026-update BiopharmaWatch en 2026-10-27T11:30:00.000Z Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2026-earnings-call BiopharmaWatch en 2026-10-27T11:30:00.000Z Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-27T11:30:00.000Z Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-case-study-iopofosine BiopharmaWatch en 2026-10-27T11:15:00.000Z Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-beam-301-phase-1-2-trial-data BiopharmaWatch en 2026-10-27T11:00:35.000Z Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress https://www.biopharmawatch.com/news/MSLE/satellos-scientific-advisory-board-regeneration-aging BiopharmaWatch en 2026-10-27T11:00:00.000Z Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-investment-conferences-november-2026 BiopharmaWatch en 2026-10-27T11:00:00.000Z Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026 https://www.biopharmawatch.com/news/HCA/hca-healthcare-reports-q3-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z HCA Healthcare Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/FTH/faeth-appoints-adam-schayowitz-board-directors BiopharmaWatch en 2026-10-27T11:00:00.000Z Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z IQVIA Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/STVN/aptar-pharma-stevanato-group-pre-filled-syringe BiopharmaWatch en 2026-10-27T11:00:00.000Z Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection https://www.biopharmawatch.com/news/STVN/stevanato-aptar-collaboration-prefilled-syringe-selection BiopharmaWatch en 2026-10-27T11:00:00.000Z Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection https://www.biopharmawatch.com/news/MASS/908-devices-third-quarter-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z 908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/RGEN/repligen-reports-q3-2026-results-and-guidance BiopharmaWatch en 2026-10-27T11:00:00.000Z Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/NRXS/neuraxis-third-quarter-2026-results-call BiopharmaWatch en 2026-10-27T11:00:00.000Z NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026 https://www.biopharmawatch.com/news/TNXP/tonix-phase-3-tonmya-fibromyalgia-data-iasp-2026 BiopharmaWatch en 2026-10-27T11:00:00.000Z Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/ARVN/arvinas-third-quarter-2026-financial-results-webcast BiopharmaWatch en 2026-10-27T11:00:00.000Z Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-27T11:00:00.000Z Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q3-2026-results-update BiopharmaWatch en 2026-10-27T11:00:00.000Z Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/BVS/bioventus-q3-fiscal-year-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/ADAG/adagene-participate-guggenheim-healthcare-conference BiopharmaWatch en 2026-10-27T11:00:00.000Z Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/FTRE/fortrea-participate-jefferies-global-healthcare-conference BiopharmaWatch en 2026-10-27T11:00:00.000Z Fortrea to Participate in Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-velinotamig-clinical-trial BiopharmaWatch en 2026-10-27T11:00:00.000Z Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA https://www.biopharmawatch.com/news/SNDL/sndl-reports-q3-2026-results BiopharmaWatch en 2026-10-27T10:55:00.000Z SNDL Reports Third Quarter 2026 Financial and Operational Results https://www.biopharmawatch.com/news/VNDA/vanda-nereus-positive-results-study-3601 BiopharmaWatch en 2026-10-27T10:50:00.000Z Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting https://www.biopharmawatch.com/news/PFE/pfizer-elrexfio-phase-3-study-results BiopharmaWatch en 2026-10-27T10:45:00.000Z Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-50-million-offering BiopharmaWatch en 2026-10-27T10:43:00.000Z Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/INFU/infusystem-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-27T10:30:00.000Z InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/CMPS/compass-pathways-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-27T10:30:00.000Z Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-doses-first-patient-corventis-trial BiopharmaWatch en 2026-10-27T10:30:00.000Z Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome https://www.biopharmawatch.com/news/IMRN/immuron-quarterly-sales-growth-october-2026 BiopharmaWatch en 2026-10-27T10:00:00.000Z Immuron continued quarterly sales growth https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q3-2026-financial-results BiopharmaWatch en 2026-10-27T10:00:00.000Z Nautilus Biotechnology Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-positive-phase-1b-results-ati-052 BiopharmaWatch en 2026-10-27T10:00:00.000Z Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma https://www.biopharmawatch.com/news/AVR/anteris-data-release-duravr-thv-tct-2026 BiopharmaWatch en 2026-10-27T10:00:00.000Z Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 https://www.biopharmawatch.com/news/CLLS/cellectis-preclinical-data-apoc3-editing-esgct-2026 BiopharmaWatch en 2026-10-27T07:15:00.000Z Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 https://www.biopharmawatch.com/news/IPHA/innate-pharma-pacific-9-trial-timing-update BiopharmaWatch en 2026-10-27T06:00:00.000Z Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 https://www.biopharmawatch.com/news/PHAR/pharming-q3-2026-financial-results-revenue-growth BiopharmaWatch en 2026-10-27T06:00:00.000Z Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November https://www.biopharmawatch.com/news/NVS/novartis-q3-2026-sales-growth-guidance BiopharmaWatch en 2026-10-27T06:00:00.000Z Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-10-27T00:10:29.000Z Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/HCM/hutchmed-savolitinib-webcast-esmo-2026 BiopharmaWatch en 2026-10-27T00:00:00.000Z Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/ULS/ul-solutions-expands-testing-facility-vietnam BiopharmaWatch en 2026-10-26T22:00:00.000Z UL Solutions Opens Expanded Product Testing Facility in Vietnam https://www.biopharmawatch.com/news/AMGN/amgen-appoints-david-gibbs-board-directors BiopharmaWatch en 2026-10-26T21:52:00.000Z AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS https://www.biopharmawatch.com/news/NYXH/nyxoah-q3-2026-financial-results-release BiopharmaWatch en 2026-10-26T21:05:00.000Z Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ONCO/onconetix-reverse-stock-split BiopharmaWatch en 2026-10-26T21:03:00.000Z Onconetix Announces Reverse Stock Split https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ifetroban-nda BiopharmaWatch en 2026-10-26T20:40:00.000Z CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261026 BiopharmaWatch en 2026-10-26T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-26T20:30:00.000Z Travere Therapeutics to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-10-26T20:30:00.000Z Sarepta Therapeutics to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/EHC/encompass-health-expands-fort-bend-county-texas BiopharmaWatch en 2026-10-26T20:30:00.000Z Encompass Health expands in Fort Bend County, Texas, with second small-format hospital in Houston area https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-26T20:15:00.000Z Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-10-26T20:15:00.000Z Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 https://www.biopharmawatch.com/news/SLBT/sl-science-holding-limited-first-half-2026-results BiopharmaWatch en 2026-10-26T20:15:00.000Z SL Science Holding Limited Reports First Half 2026 Financial Results https://www.biopharmawatch.com/news/LYCA/lycia-therapeutics-ipo-closing-october-2026 BiopharmaWatch en 2026-10-26T20:12:00.000Z Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/CLOV/clover-health-ubs-global-healthcare-conference-2026 BiopharmaWatch en 2026-10-26T20:05:29.000Z Clover Health to Participate in Upcoming UBS Global Healthcare Conference https://www.biopharmawatch.com/news/RXRX/recursion-webinar-updated-rec-4881-data-november-3 BiopharmaWatch en 2026-10-26T20:05:00.000Z Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 https://www.biopharmawatch.com/news/OABI/omniab-participate-investor-conferences-november BiopharmaWatch en 2026-10-26T20:05:00.000Z OmniAb to Participate in Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/OSUR/orasure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-26T20:05:00.000Z OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-announces-new-employee-inducement-grants-20261026 BiopharmaWatch en 2026-10-26T20:01:00.000Z Definium Therapeutics Announces New Employee Inducement Grants https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-10-26T20:01:00.000Z Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 https://www.biopharmawatch.com/news/RDNT/radnet-acquires-onrad BiopharmaWatch en 2026-10-26T20:01:00.000Z RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc. https://www.biopharmawatch.com/news/PFE/talzenna-xtandi-fda-approval-prostate-cancer BiopharmaWatch en 2026-10-26T17:41:00.000Z Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting https://www.biopharmawatch.com/news/PFE/pfizer-talzenna-xtandi-fda-approval-prostate-cancer BiopharmaWatch en 2026-10-26T17:41:00.000Z Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-growth-fiscal-q4-2026 BiopharmaWatch en 2026-10-26T17:00:00.000Z Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261026 BiopharmaWatch en 2026-10-26T15:57:00.000Z Novo Nordisk A/S - share repurchase programme